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Objective: To assess the effect of obesity on 6-month post-operative complications following total knee
(TKR) or hip (THR) replacement.
Design: Data for patients undergoing ﬁrst THR or TKR between 1995 and 2011 was taken from the
Clinical Practice Research Datalink. Logistic regression was used to assess whether body mass index
(BMI) was associated with 6-month post-operative complications [deep vein thrombosis or pulmonary
embolism (DVT/PE), myocardial infarction (MI), stroke, respiratory infection, anaemia, wound infection,
urinary tract infection or death] after controlling for the effects of age, gender, smoking, drinking, socio-
economic status (SES), co-morbidities and medications.
Results: 31,817 THR patients and 32,485 TKR patients were identiﬁed for inclusion. Increasing BMI was
associated with a signiﬁcantly higher risk of wound infections, from 1.6% to 3.5% in THR patients
(adjusted P < 0.01), and from 3% to 4.1% (adjusted P < 0.05) in TKR patients. DVT/PE risk also increased
with obesity from 2.2% to 3.3% (adjusted P < 0.01) in THR patients and from 2.0% to 3.3% (adjusted
P < 0.01) in TKR patients. Obesity was not associated with increased risk of other complications.
Conclusion: Whilst an increased risk of wound infection and DVT/PE was observed amongst obese pa-
tients, absolute risks remain low and no such association was observed for MI, stroke and mortality.
However this is a selected cohort (eligible for surgery according to judgement of NHS GPs and surgeons)
and as such these results do not advocate surgery be given without consideration of BMI, but indicate
that universal denial of surgery based on BMI is unwarranted.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Background
Total hip replacement (THR) and total knee replacement (TKR)
surgeries are common and successful surgical interventions,
providing substantial pain relief and improvement in functionalA. Judge, The Botnar Research
d Orthopaedic Centre, Wind-
837.
.uk (G. Wallace), andrew.
toalhambra@ndorms.ox.ac.uk
nigel.arden@ndorms.ox.ac.uk
ternational. Published by Elsevier Ldisability for patients with hip and knee arthritis1e5. It is generally
acknowledged that the key indications for surgery include joint
pain, functional limitation and radiographic evidence of
arthritis6e8. There is no consensus on the severity of symptoms that
indicate surgery is required7,9, and no universally accepted criteria
to determine the indications for surgery6 with many other factors
such as age, obesity, co-morbidities, smoking, alcohol use, attempts
at non-surgical treatments, and psychological factors potentially
inﬂuencing the decision to perform or delay surgery7,10,11.
Whilst some authors conclude that increasing obesity is asso-
ciated with worse pain and functional outcomes following
joint replacement12e15, others have found no evidence of antd. All rights reserved.
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still expect large symptomatic improvement and satisfaction, even
though they may not attain the same level of post-operative pain
and function scores22,23.
However there is growing evidence that commissioners in the
UK are restricting access or encouraging weight loss prior to joint
replacement surgery for obese patients24e28, stating that increasing
levels of obesity increase the risk of complications. Surgeons have
also expressed concerns that surgery is more difﬁcult in obese
patients with a perceived increased risk of complications29. Within
the literature there is limited evidence to support this view,
although such risks are more consistently observed amongst the
morbidly obese [body mass index e BMI  40 kg/m2]16,29e35.
The aim of this paper is to study the association between obesity
and the risk of 6-month post-operative complications following
THR or TKR in routinely collected UK data representative of actual
clinical practice.
Methods
Source of data and study participants
NHS observational data for UK GP practices from the Clinical
Practice Research Datalink (CPRD) (formerly the General Practice
Research Database) was screened for all patients receiving a ﬁrst
primary THR or TKR between 1st January 1995 and 11th August
2011. To meet the inclusion criteria THR patients must have had no
record of a previous primary hip replacement ever or any record of
a primary total or uni-compartmental knee replacement in the 6
months prior to THR. Similarly, TKR patients must have had no
record of a previous primary knee replacement ever nor any record
of a primary total hip or uni-compartmental knee replacement in
the 6 months prior to TKR. Further all patients must have had no
knee or hip revision operation in the 6 months prior to TKR or THR,
at least one valid BMI measure (between 10 kg/m2 and 70 kg/m2) in
the 5 years prior to the TKR or THR, and at least 6 months subse-
quent follow-up prior to transferring out of the GP practice (unless
the reason was death).
Outcomes
All patients meeting the inclusion criteria were followed up to
ascertain whether they had a record of any of the following out-
comes during the 6 months immediately following THR or TKR;
deep vein thrombosis or pulmonary embolism (DVT/PE), myocar-
dial infarction (MI), stroke, respiratory infection, anaemia, wound
infection, urinary tract infection (UTI) or death. The validity of di-
agnoses in CPRD and their utility in epidemiological studies have
been well documented36.
Exposure: obesity
BMI measurements as coded by GPs and other staff in primary
care records were identiﬁed, and the closest prior to index surgery
was considered in these analyses. BMI was categorized according to
the World Health Organization categories: underweight (<18.5 kg/
m2), normal (18e25 kg/m2), overweight (25e30 kg/m2), obese class
I (30e35 kg/m2), obese class II (35e40 kg/m2), or obese class III
(>40 kg/m2).
Statistical analyses
For each operation (THR or TKR), logistic regression methods
were used to assess whether the likelihood of experiencing each
outcome varied by BMI category. Robust standard errors adjustingfor clustering of patients within GP practices were used. Adjust-
ment was made for potential confounding variables including:
gender, age at operation, smoking (current, ex, never), drinking
(current, ex, never), practice level socio-economic status (SES)
(Index of Multiple Deprivation (IMD) quintiles), year of surgery
(1995e2000, 2000e2005 or 2005 and later), previous record of
diabetes, chronic pulmonary obstructive disease (COPD), ischaemic
heart disease or atrial ﬁbrillation, previous use of anti-
hypertensives, statins, antidepressants, antibiotics, aspirin, or an-
ticoagulants and previous record of the outcome in question. Pre-
vious record of a comorbidity or previous use of a medication was
deﬁned as any relevant record at anytime between registration and
surgery date.
As sensitivity analyses further adjustment was made for any
records of THR, TKR or uni-compartmental knee replacement and
knee or hip revision operations in the 6 months following initial
THR or TKR.
In all analyses excluding that where death was the outcome,
only patients who survived the 6 months following the operation
were included. To address any potential selection bias that this
might introduce, a sensitivity analysis was conducted including all
patients irrespective of whether death occurred in the 6-month
period.
Results
Hip Replacement Cohort
Between 1995 and August 2011, 53,337 patients were identiﬁed
with a ﬁrst record of a THR in CPRD. Of these 505 were excluded
due to records of other joint operations in the 6 months prior to
THR, 559 left the practice before the end of the 6-month follow-up
period and 20,456 did not have a relevant BMI measure. In total,
31,817 patients met the inclusion criteria (Fig. 1). Of these, 462
patients (1.5%) were underweight, 9006 (28%) were of normal
weight, 12,619 (40%) were overweight, 6809 (21%) were obese class
I, 2224 (7%) obese class II and 697 (2%) obese class III. Baseline
characteristics for study participants in the Hip Replacement
Cohort are shown in Table I.
Incidence rates for each of the outcomes range from0% to 4.1% in
the 6 months following THR (Table III). 307 individuals died within
the 6-month follow-up period and were therefore excluded from
the analysis of outcomes other than death.
Increasing BMI from 25 kg/m2 to 35 kg/m2þwas associatedwith
a progressive and signiﬁcant increased risk of wound infections
within 6 months, with risk increasing from 1.6% in patients with
BMI 20e25 kg/m2 to 3.5% in patients with BMI over 35 kg/m2
[adjusted odds ratio (OR) range from 1.34 to 2.18; all P < 0.01]. A
similar pattern was observed for DVT/PE [risk increases from 2.2%
to 3.3% in themoderately obese (30e35 kg/m2)]. Interestingly there
was some suggestion that above 35 kg/m2, the outcome incidence
reduces back (unadjusted risk of 3.1%) to being more in the range of
that observed in overweight (25e30 kg/m2) patients (>35 kg/m2
OR ¼ 1.51; 95% CI 1.16e1.96; 25e30 kg/m2 OR ¼ 1.39; 95% CI
1.16e1.66), although there was not a statistically signiﬁcant differ-
ence in the risk experienced in the moderately and severely obese.
For outcomes of respiratory infection, UTI, anaemia, MI and stroke,
increasing BMI was not associated with a change in risk (Table III).
Multivariable analysis also indicates that being underweight
(BMI <18.5 kg/m2) may be protective for the outcomes of DVT/PE
(OR ¼ 0.75; 95% CI 0.35e1.60), MI (OR ¼ 0.70; 95% CI 0.09e5.39)
and stroke (OR ¼ 0.56; 95% CI 0.07e4.69), although these did not
reach statistical signiﬁcance (P ¼ 0.454; 0.734 and 0.595 respec-
tively) likely reﬂecting the small number of underweight patients
in this cohort (n ¼ 443 excluding 19 deaths) and the very few
Fig. 1. Flow chart illustrating inclusion and exclusion criteria for THR and TKR Cohorts.
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Stroke n ¼ 3).
Being underweight (<18.5 kg/m2) was associated with a
signiﬁcantly increased 6-month mortality (OR ¼ 2.71; 95% CI
1.67e4.39; P < 0.001), whilst being over 25 kg/m2 is associated with
a signiﬁcantly reduced mortality [OR range 0.61e0.65;
P < 0.001e0.147 (Table III)] compared to normal weight
participants.
The results of the sensitivity analyses were highly similar to
those of the primary analyses, indicating that death was not a
signiﬁcant competing risk and therewas no signiﬁcant survival bias
(data not shown).
Knee Replacement Cohort
Between 1995 and August 2011, 49,200 patients were identiﬁed
with a ﬁrst record of TKR in CPRD. Of these 573 were excluded due
to records of other joint operations in the 6 months prior to TKR. Of
the remaining patients, 411 left the practice before completion of
the 6-month follow-up period and 15,731 did not have a relevant
BMI measure. In total 32,485 patients met the inclusion criteria, of
these 58% were female with an average age of 70 years. The dis-
tribution of BMI amongst TKR patients differed from that amongst
THR patients with 138 patients (<1%) being underweight, 5396
(17%) of normal weight, 12,403 (38%) overweight, 9272 (29%) obese
class I, 3829 (12%) obese class II and 1447 (4%) obese class III.
Baseline characteristics for the Knee Replacement Cohort partici-
pants are shown in Table II. Incidence rates for each of the outcomes
range from 0% to 5.1% in the 6 months following TKR (Table IV).
182 individuals died within the 6-month follow-up period and
were therefore excluded from the analysis of outcomes other than
death. Due to the small number of individuals that were classiﬁed
as underweight these individuals were dropped from analyses
where necessary and not combined with the normal weight pa-
tients given the clear differences between these two groups of
patients.The results of the multivariable analyses indicate that increasing
BMI from 25 kg/m2 to 35 kg/m2þ is associated with a progressive
and signiﬁcant increased risk of PE/DVT within 6 months, with risk
increasing from 2.0% in patients with BMI 20e25 kg/m2 to 3.3% in
patients with BMI over 35 kg/m2 (adjusted OR range from 1.41 to
1.93; all P < 0.01). A similar, albeit weaker, associationwas observed
for wound infection, however an increased risk was only observed
amongst patients with BMI 30 kg/m2 and over increasing from 3%
to 4.1% (30e35 kg/m2 adjusted OR ¼ 1.23; 95% CI 1.01e1.50;
P¼ 0.04; >35 kg/m2 adjusted OR¼ 1.39; 95% CI 1.11e1.72; P < 0.01).
For outcomes of respiratory infection, UTI, anaemia, MI and stroke,
there was no statistical evidence that increasing BMI was associ-
ated with a change in risk. This was also the case for 6-month
mortality, although as for THR patients an elevated risk was
observed amongst underweight patients (OR ¼ 4.61; 95% CI
1.64e13.01; P < 0.01). The decreased risk amongst obese patients
(seen in the THR patients) was not observed amongst the TKR pa-
tients following adjustment for confounders.
The results of the sensitivity analyses did not differ substantially
from those of the primary analyses (data not shown), indicating
that death was not a signiﬁcant competing risk and there was no
signiﬁcant survival bias.
Discussion
These data suggest that complications following THR or TKR are
rare. The large sample size available enabled us to detect small but
signiﬁcant increases in the rates of wound infections and thrombo-
embolic (DVT/PE) events amongst the more obese patients, whilst
no such associationwas observed for other complications including
major cardiovascular outcomes (MI and stroke), and other (urinary
and respiratory) common infections in the post-operative period.
However it is important to interpret these ﬁndings in consid-
eration of the inherent selection biases present as a result of this
being an observational study of patients selected for surgery in NHS
actual practice scenarios. Accordingly these results do not advocate
Table I
Baseline characteristics of THR patients by BMI category prior to surgery
Underweight Normal Overweight Obese 1 Obese 2 Obese 3 Missing
<18.5 kg/m2 18.5e25 kg/m2 25e30 kg/m2 30e35 kg/m2 35e40 kg/m2 >40 kg/m2
N 462 9006 12,619 6809 2224 697 20,456
Age 73.0 (12.8) 70.9 (11.5) 69.5 (10.3) 67.5 (9.9) 65.0 (9.9) 62.9 (9.4) 69.3 (11.6)
Male 68 (15%) 2786 (31%) 5520 (44%) 2764 (41%) 784 (35%) 165 (24%) 7839 (38%)
Female 394 (85%) 6220 (69%) 7099 (56%) 4045 (59%) 1440 (65%) 532 (76%) 12,617 (62%)
Drinking: Yes 321 (70%) 6839 (76%) 9799 (78%) 5178 (76%) 1568 (71%) 444 (64%) 13,418 (66%)
Drinking: No 69 (15%) 1036 (12%) 1318 (10%) 689 (10%) 270 (12%) 116 (17%) 2462 (12%)
Drinking: Ex 56 (12%) 849 (9%) 1170 (9%) 721 (11%) 293 (13%) 114 (16%) 1062 (5%)
Missing 16 (4%) 282 (3%) 332 (3%) 221 (3%) 93 (4%) 23 (3%) 3514 (17%)
Smoking: Yes 103 (22%) 1250 (14%) 1252 (10%) 643 (9%) 226 (10%) 59 (9%) 2612 (13%)
Smoking: No 230 (50%) 4705 (52%) 6267 (50%) 3207 (47%) 986 (44%) 350 (50%) 11,267 (55%)
Smoking: Ex 127 (28%) 3036 (34%) 5091 (40%) 2950 (43%) 1010 (45%) 287 (41%) 5852 (29%)
Missing 2 (0.4%) 15 (0.2%) 9 (0.1%) 9 (0.1%) 2 (0.1%) 1 (0.1%) 725 (4%)
SES quintile 1 83 (18%) 1980 (22%) 2588 (21%) 1310 (19%) 374 (17%) 134 (19%) 4532 (22%)
SES quintile 2 104 (23%) 1983 (22%) 2716 (22%) 1375 (20%) 442 (20%) 149 (21%) 4695 (23%)
SES quintile 3 99 (21%) 1771 (20%) 2586 (21%) 1383 (20%) 468 (21%) 141 (20%) 4231 (21%)
SES quintile 4 100 (22%) 1952 (22%) 2786 (22%) 1570 (23%) 551 (25%) 143 (21%) 3968 (19%)
SES quintile 5 76 (17%) 1320 (15%) 1943 (15%) 1171 (17%) 389 (18%) 130 (19%) 3030 (15%)
Pre-diabetes 15 (3%) 616 (7%) 1258 (10%) 1039 (15%) 420 (19%) 161 (23%) 299 (1.5%)
Pre-COPD 5 (1%) 56 (1%) 70 (1%) 41 (1%) 11 (0.5%) 4 (1%) 18 (0.1%)
Pre-ischemic heart disease (IHD) 38 (8%) 823 (9%) 1329 (11%) 779 (11%) 224 (10%) 51 (7%) 1200 (6%)
Pre-hypertension 113 (25%) 2684 (30%) 4543 (36%) 2964 (44%) 1010 (45%) 334 (48%) 4525 (22%)
Pre-atrial ﬁbrillation 28 (6%) 487 (5%) 647 (5%) 334 (5%) 113 (5%) 32 (5%) 790 (4%)
Pre-antibiotics 307 (66%) 6056 (67%) 8705 (69%) 4978 (73%) 1694 (76%) 557 (80%) 11,336 (55%)
Pre-anticoagulants 20 (4%) 440 (5%) 677 (5%) 422 (6%) 150 (7%) 52 (7%) 782 (4%)
Pre-aspirin 109 (24%) 2409 (27%) 3780 (30%) 2203 (32%) 737 (33%) 196 (28%) 3414 (17%)
Pre-antihypertensives 8 (2%) 244 (3%) 533 (4%) 323 (5%) 92 (4%) 26 (4%) 450 (2%)
Pre-statins 67 (15%) 2099 (23%) 3999 (32%) 2558 (38%) 853 (38%) 257 (37%) 2280 (11%)
Pre-antidepressants 178 (39%) 2737 (30%) 3701 (29%) 2328 (34%) 860 (39%) 310 (45%) 4812 (24%)
Pre-PE or DVT 10 (2%) 295 (3%) 446 (4%) 315 (5%) 122 (6%) 44 (6%) 731 (4%)
Pre-wound infection 13 (3%) 195 (2%) 344 (3%) 259 (4%) 113 (5%) 36 (5%) 440 (2%)
Pre-respiratory infection 54 (12%) 797 (9%) 1100 (9%) 729 (11%) 214 (10%) 65 (9%) 1527 (7%)
Pre-UTI 99 (21%) 1598 (18%) 2116 (17%) 1245 (18%) 434 (20%) 146 (21%) 3039 (15%)
Pre-haemorrhagic stroke 1 (0.2%) 22 (0.2%) 27 (0.2%) 12 (0.2%) 5 (0.2%) 1 (0.1%) 20 (0.1%)
Pre-anaemia 47 (10%) 595 (7%) 632 (5%) 334 (5%) 121 (5%) 38 (6%) 874 (4%)
Pre-MI 19 (4%) 424 (5%) 684 (5%) 377 (6%) 118 (5%) 21 (3%) 538 (3%)
Pre-stroke 9 (2%) 187 (2%) 237 (2%) 137 (2%) 34 (2%) 10 (1%) 278 (1%)
Record of other joint op
in following 6 m (excl hip)
2 (0.4%) 65 (1%) 123 (1%) 91 (1%) 23 (1%) 14 (2%) 171 (1%)
Record of other hip op
in following 6 m
46 (10%) 1256 (14%) 1789 (14%) 954 (14%) 331 (15%) 86 (12%) 2869 (14%)
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should not automatically prohibit a patient from surgery and that
current selection after accurate clinical assessment of eligible pa-
tients by GPs, anaesthetists and orthopaedic surgeons is sufﬁcient
to ensure that those obese patients selected for surgery are not at a
signiﬁcantly increased risk of serious complications, with the ex-
ceptions mentioned above.
The observed rates of all complications following THR or TKR
were low. For both operations, rates of stroke and MI within 6
months were under 0.5%, and for respiratory infections this was
only marginally higher at slightly under 0.6%. Whilst anaemia, UTI,
wound infection and PE/DVT were observed with higher rates,
these were still below 3% with the exception of wound infections,
which appear to be more common following TKR (3.4% vs 2.2% in
THR). Accounting for differing lengths of follow-up, the rates of
DVT/PE37, MI38, stroke39 observed were not out of line with esti-
mates from other cohort studies. It is reassuring that the more
common complications are those for which prophylaxis is most
readily available.
A strong positive association was observed between increasing
BMI and risk of wound infection and PE/DVT. The absolute risk
remains low in obese patients however, with rates of wound
infection increasing to 3.5% (from 1.6%) and 4.1% (from 3.0%) in THR
and TKR patients respectively. Similarly the risk of PE/DVT
remained low at 3.3% (from 2.2% and 2.0% for THR and TKRrespectively). The ﬁnding of an association between obesity and
wound infections is consistent with existent literature, which
consistently demonstrates such increased risk across all manner of
surgeries40e48 including orthopaedic procedures49,50. In some
studies the association appeared to be limited to the obese or
morbidly obese which is somewhat consistent with ﬁndings of this
study which demonstrated an increased risk only at BMI greater
than 30 kg/m2 amongst TKR patients and a further increased risk in
those with BMI >35 kg/m2.
The literature on post-operative risk of thrombo-embolic events
is less comprehensive but similarly consistent with many re-
searchers observing increasing risk with obesity51e53 although this
has not been replicated consistently in the orthopaedic literature50.
Interestingly in this study we also observe a strong doseeresponse
relationship (THR OR ¼ 1.39e1.64; TKR OR ¼ 1.41e1.93) suggesting
that even moderately overweight or obese patients experience a
signiﬁcantly increased risk of such events.
It was not possible to assess the effect of being underweight on
the risk of thrombo-embolic events (or MI) following TKR since the
low incidence of these events combined with the few underweight
patients meant that no events were observed for this group. Since
the analysis of the THR Cohort indicated underweight patients do
not share the same risk proﬁle as normal weight patients, dropping
the underweight patients from these analyses was considered
preferable to combining them with the normal weight patients.
Table II
Baseline characteristics of TKR patients by BMI category prior to surgery
Underweight Normal Overweight Obese 1 Obese 2 Obese 3 Missing
<18.5 kg/m2 18.5e25 kg/m2 25e30 kg/m2 30e35 kg/m2 35e40 kg/m2 >40 kg/m2
N 138 5396 12,403 9272 3829 1447 15,731
Age 71.5 (12.5) 72.7 (10.1) 71.1 (8.9) 68.6 (8.7) 66.3 (8.5) 64.1 (8.4) 70.4 (10.0)
Male 19 (14%) 2119 (39%) 6063 (49%) 3927 (42%) 1170 (31%) 326 (23%) 6726 (43%)
Female 119 (86%) 3277 (61%) 6340 (51%) 5345 (58%) 2659 (69%) 1121 (77%) 9005 (57%)
Drinking: Yes 82 (59%) 4051 (75%) 9602 (77%) 6866 (74%) 2671 (70%) 945 (65%) 10,374 (66%)
Drinking: No 29 (21%) 614 (11%) 1247 (10%) 1046 (11%) 506 (13%) 217 (15%) 2103 (13%)
Drinking: Ex 23 (17%) 576 (11%) 1214 (10%) 1107 (12%) 510 (13%) 226 (16%) 983 (6%)
Missing 4 (3%) 155 (3%) 340 (3%) 253 (3%) 142 (4%) 59 (4%) 2271 (14%)
Smoking: Yes 28 (20%) 536 (10%) 1022 (8%) 690 (7%) 304 (8%) 101 (7%) 1589 (10%)
Smoking: No 72 (52%) 2870 (53%) 5915 (48%) 4419 (48%) 1868 (49%) 719 (50%) 8954 (58%)
Smoking: Ex 38 (28%) 1986 (37%) 5451 (44%) 4160 (45%) 1650 (43%) 626 (43%) 4838 (31%)
Missing 0 (0%) 4 (0.1%) 15 (0.1%) 3 (0.3%) 7 (0.1%) 1 (0.1%) 350 (2%)
SES quintile 1 23 (17%) 1152 (21%) 2339 (19%) 1582 (17%) 603 (16%) 229 (16%) 3383 (22%)
SES quintile 2 24 (17%) 1184 (22%) 2571 (21%) 1882 (20%) 736 (19%) 276 (19%) 3362 (21%)
SES quintile 3 34 (25%) 1047 (19%) 2558 (21%) 1941 (21%) 806 (21%) 295 (20%) 3322 (21%)
SES quintile 4 36 (26%) 1132 (21%) 2864 (23%) 2120 (23%) 908 (24%) 346 (24%) 3113 (20%)
SES quintile 5 21 (15%) 881 (16%) 2071 (17%) 1747 (19%) 776 (20%) 301 (21%) 2551 (16%)
Pre-diabetes 5 (4%) 410 (8%) 1464 (12%) 1635 (18%) 803 (21%) 370 (26%) 267 (2%)
Pre-COPD 0 (0%) 27 (0.5%) 77 (1%) 65 (1%) 32 (1%) 9 (1%) 8 (0.1%)
Pre-IHD 9 (7%) 611 (11%) 1451 (12%) 1070 (12%) 370 (10%) 120 (8%) 970 (6%)
Pre-hypertension 33 (24%) 1720 (32%) 4894 (39%) 4242 (46%) 1877 (49%) 736 (51%) 4190 (27%)
Pre-atrial ﬁbrillation 0 (0%) 27 (0.5%) 53 (0.4%) 45 (0.5%) 22 (1%) 4 (0.3%) 69 (0.4%)
Pre-antibiotics 12 (9%) 360 (7%) 840 (7%) 618 (7%) 257 (7%) 104 (7%) 1137 (7%)
Pre-anticoagulants 0 (0%) 38 (1%) 74 (1%) 67 (1%) 30 (1%) 12 (1%) 102 (1%)
Pre-aspirin 2 (1%) 149 (3%) 341 (3%) 268 (3%) 116 (3%) 35 (2%) 386 (2%)
Pre-antihypertensives 4 (3%) 192 (4%) 769 (6%) 602 (6%) 200 (5%) 62 (4%) 471 (3%)
Pre-statins 21 (15%) 1595 (30%) 4622 (37%) 3905 (42%) 1616 (42%) 604 (42%) 2204 (14%)
Pre-antidepressants 61 (44%) 1697 (31%) 3812 (31%) 3202 (35%) 1493 (39%) 639 (44%) 3911 (25%)
Pre-PE or DVT 3 (2%) 202 (4%) 557 (4%) 488 (5%) 225 (6%) 93 (6%) 693 (4%)
Pre-wound infection 6 (4%) 153 (3%) 448 (4%) 434 (5%) 204 (5%) 84 (6%) 433 (3%)
Pre-respiratory infection 12 (9%) 505 (9%) 1166 (9%) 1007 (11%) 459 (12%) 203 (14%) 1380 (9%)
Pre-UTI 37 (27%) 972 (18%) 2193 (18%) 1743 (19%) 781 (20%) 306 (21%) 2484 (16%)
Pre-haemorrhagic stroke 0 (0%) 12 (0.2%) 12 (0.1%) 8 (0.1%) 7 (0.2%) 5 (0.4%) 22 (0.1%)
Pre-anaemia 24 (17%) 459 (9%) 716 (6%) 522 (6%) 243 (6%) 105 (7%) 793 (5%)
Pre-MI 4 (3%) 287 (5%) 669 (5%) 506 (5%) 147 (4%) 46 (3%) 396 (3%)
Pre-stroke 0 (0%) 125 (2%) 250 (2%) 191 (2%) 67 (2%) 24 (2%) 217 (1%)
Record of other joint op
in following 6 m (excl knee)
1 (1%) 50 (1%) 103 (1%) 54 (1%) 22 (1%) 13 (0.9%) 145 (1%)
Record of other knee op
in following 6 m
17 (12%) 893 (17%) 2062 (17%) 1489 (16%) 606 (16%) 239 (17%) 2631 (17%)
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the association between underweight and these outcomes in TKR
patients would be beneﬁcial in future research.
No associations between BMI and risk of other post-operative
complications (MI, stroke, respiratory infection, anaemia or UTI)
were observed. UTI and anaemia were similarly frequent as wound
infections and PE/DVT, suggesting that the study was not under-
powered to detect such effects. The literature regarding the effects
of obesity on the risk of UTI following surgery is minimal. Of the few
studies known to the researchers, effects have been observed with
severe and morbid obesity amongst elderly patients undergoing
hip and knee surgery54. Many other studies attempting to look at
UTI complications did not observe sufﬁcient numbers of events to
investigate the effects of obesity. The authors are not aware of any
published research looking at anaemia as a complication following
surgery outside of the bariatric surgery literature. Such literature is
not commented on here given the continued consequences of such
surgery on dietary intake, the primary source of iron, which is not
comparable to joint replacement.
The ﬁndings for cardiovascular complications are far from
consistent, with some studies observing no association between
obesity and events such as stroke40 or MI40 following surgery,
whilst others ﬁnd strong associations with cardiopulmonary com-
plications52,55 such as atrial ﬁbrillation40 or hypoxaemia56. How-
ever as noted above, within the current study there are likely to be
signiﬁcant selection biases in terms of which patients are selectedfor surgery. These biases could have impacted the associations
between obesity and the risk of complications following surgery
and are discussed in detail below.
The literature regarding post-operative respiratory infections is
also varied with morbid obesity having been associated with res-
piratory infection amongst elderly patients undergoing hip and
knee surgery50,54 and obesity having been associated with
increasing the risk of pulmonary complications in other sur-
geries44,52,55 patients; whilst other studies have observed no such
associations57. This inconsistency is perhaps unsurprising with
many studies being small and investigating multiple end-points
thereby being underpowered to detect signiﬁcant differences in
these rarer complications. Whilst a major strength of the present
study is its very large sample size of over 30,000 THR and TKR,
given the rarity of many post-operative complications and the
relatively small numbers of morbidly obese patients (n ¼ 697 THR;
n ¼ 1447 TKR) the sample size may still not be sufﬁcient to detect
the signiﬁcant differences observed elsewhere.
Mortality rates in the 6 months following THR and TKR in the
current study were on the whole low with rates well below 1% in
normal weight and above patients undergoing TKR, and overweight
and above patients undergoing THR (normal weight patients un-
dergoing THR had a slightly higher mortality at 1.4%). This is
comparable to rates reported in the latest NJR annual report with
90-day mortality of 0.5% and 1-year mortality of 1.5%58. Amongst
the underweight patients however, there was a signiﬁcantly
Table III
Incidence and crude and adjusted ORs for post-operative complications following THR
Number (%) with outcome Unadjusted Adjusted*
n ¼ 31,510 n ¼ 30,553
6 Months PE þ DVT
<18.5 7 1.5% 0.71 (0.33e1.51) 0.372 0.75 (0.35e1.60) 0.454
18.5e25 200 2.2% REF REF
25e30 379 3.0% 1.33 (1.12e1.58) 0.001 1.39 (1.16e1.66) <0.001
30e35 224 3.3% 1.50 (1.24e1.82) <0.001 1.64 (1.34e2.00) <0.001
35þ 90 3.1% 1.36 (1.05e1.76) 0.018 1.51 (1.16e1.96) 0.002
6 Months wound infection
<18.5 7 1.5% 0.97 (0.45e2.08) 0.931 1.03 (0.48e2.19) 0.941
18.5e25 145 1.6% REF REF
25e30 276 2.2% 1.35 (1.10e1.66) 0.004 1.34 (1.09e1.64) 0.006
30e35 173 2.5% 1.54 (1.23e1.93) <0.001 1.52 (1.21e1.90) <0.001
35þ 103 3.5% 2.17 (1.68e2.81) <0.001 2.18 (1.67e2.86) <0.001
6 Months respiratory infection
<18.5 5 1.1% 1.75 (0.63e4.88) 0.286 1.49 (0.54e4.12) 0.439
18.5e25 48 0.5% REF REF
25e30 63 0.5% 0.97 (0.66e1.42) 0.878 1.02 (0.68e1.54) 0.915
30e35 46 0.7% 1.31 (0.87e1.98) 0.191 1.34 (0.86e2.06) 0.192
35þ 10 0.3% 0.66 (0.33e1.32) 0.24 0.72 (0.36e1.45) 0.364
6 Months UTI
<18.5 15 3.2% 1.33 (0.77e2.30) 0.312 1.18 (0.68e2.03) 0.557
18.5e25 217 2.4% REF REF
25e30 285 2.3% 0.94 (0.79e1.13) 0.528 1.05 (0.88e1.25) 0.603
30e35 182 2.7% 1.11 (0.91e1.36) 0.301 1.25 (1.02e1.55) 0.036
35þ 72 2.5% 1.03 (0.79e1.36) 0.809 1.18 (0.88e1.58) 0.260
6 Months anaemia
<18.5 13 2.8% 1.20 (0.68e2.12) 0.528 1.03 (0.57e1.86) 0.928
18.5e25 220 2.4% REF REF
25e30 284 2.3% 0.90 (0.76e1.08) 0.275 0.93 (0.76e1.14) 0.498
30e35 162 2.4% 0.97 (0.79e1.19) 0.76 1.03 (0.83e1.28) 0.789
35þ 76 2.6% 1.07 (0.82e1.39) 0.629 1.10 (0.83e1.45) 0.515
6 Months MI
<18.5 1 0.2% 0.67 (0.09e4.90) 0.691 0.70 (0.09e5.39) 0.734
18.5e25 34 0.4% REF REF
25e30 58 0.5% 1.30 (0.83e2.03) 0.248 1.19 (0.77e1.84) 0.436
30e35 23 0.3% 1.01 (0.58e1.73) 0.983 1.02 (0.59e1.77) 0.944
35þ 11 0.4% 0.92 (0.43e1.93) 0.819 1.05 (0.47e2.37) 0.904
6 Months stroke
<18.5 4 0.9% 1.43 (0.44e4.64) 0.548 0.56 (0.07e4.69) 0.595
18.5e25 47 0.5% REF REF
25e30 56 0.4% 0.84 (0.56e1.27) 0.416 0.93 (0.60e1.44) 0.752
30e35 38 0.6% 1.16 (0.74e1.80) 0.519 1.36 (0.85e2.19) 0.199
35þ 11 0.4% 0.80 (0.41e1.56) 0.51 1.24 (0.59e2.58) 0.571
6 Months death n ¼ 31,817 n ¼ 30,844
<18.5 19 4.1% 2.93 (1.79e4.78) <0.001 2.71 (1.67e4.39) <0.001
18.5e25 130 1.4% REF REF
25e30 96 0.8% 0.52 (0.40e0.68) <0.001 0.61 (0.46e0.81) 0.001
30e35 45 0.7% 0.45 (0.32e0.64) <0.001 0.62 (0.43e0.90) 0.013
35þ 17 0.6% 0.40 (0.24e0.66) <0.001 0.65 (0.36e1.16) 0.147
* Adjusted for age; gender; drinking; smoking; SES; year of surgery; previous occurrence of outcome; prior use of statins, antihypertensives, aspirin, antidepressants,
anticoagulants, antibiotics; previous diagnosis of diabetes, hypertension, chronic obstructive pulmonary disease, atrial ﬁbrillation, ischaemic heart disease.
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patients. Underweight may be a marker for increased comorbidity.
Since low BMI is also a risk factor for hip fracture59 which is asso-
ciated with signiﬁcantly increased mortality60, the high mortality
observed amongst underweight THR patients may also reﬂect that
a higher proportion of these operations were a result of hip frac-
ture. In other words the increased risk of mortality amongst un-
derweight patients may not reﬂect a consequence of the surgery
itself. In contrast obesity appeared to be protective against 6-month
mortality with the lowest rates (THR 0.6%; TKR 0.3%) observed in
patients with BMI >35 kg/m2. This ﬁnding is not reﬂected in much
surgical literature where obesity is observed to be a risk factor for
post-operative mortality61 or neutral40,44,52. It is noted however
that unlike many surgeries, THR and TKR are elective and bothpatient and surgeon have a greater element of choice. It is therefore
highly plausible that there is bias in the selection for these sur-
geries, with GPs referring and surgeons selecting the healthiest
obese class II and III patients, whilst such criteria are not applied to
normal weight patients. Such selection bias may also explain the
lack of association observed between MI or stroke and obesity,
which would usually be expected in a non-surgical cohort62e64.
A limitation of the current study is potential measurement error
and misclassiﬁcation that are well documented in observational
studies. For example, in ascertaining comorbidity status we
considered all relevant diagnoses or medications since enrolment.
This is unlikely to perfectly discriminate amongst health statuses of
participants at the time of surgery. The time available between
enrolment and surgery was however materially comparable
Table IV
Incidence and crude and adjusted ORs for post-operative complications following TKR
Number (%) with Outcom Unadjusted Adjusted*
n ¼ 32,303 n ¼ 31,356
6 Months PE þ DVT n ¼ 32,169 n ¼ 31,226
<18.5 0 0.0% DROPPED DROPPED
18.5e25 107 2.0% REF REF
25e30 334 2.7% 1.35 (1.08e1.68) 0.008 1.41 (1.13e1.75) 0.002
30e35 275 3.0% 1.46 (1.16e1.83) 0.001 1.59 (1.26e1.99) <0.001
35þ 174 3.3% 1.65 (1.29e2.11) <0.001 1.93 (1.45e2.57) <0.001
6 Months wound infection
<18.5 4 2.9% 1.00 (0.37e2.74) >0.999 0.97 (0.36e2.67) 0.960
18.5e25 162 3.0% REF REF
25e30 371 3.0% 1.00 (0.83e1.21) >0.999 0.98 (0.81e1.19) 0.836
30e35 347 3.7% 1.26 (1.04e1.52) 0.018 1.23 (1.01e1.50) 0.042
35þ 216 4.1% 1.39 (1.13e1.71) 0.002 1.39 (1.11e1.72) 0.003
6 Months respiratory infection
<18.5 1 0.7% 1.21 (0.16e8.93) 0.849 1.10 (0.20e6.05) 0.913
18.5e25 35 0.6% REF REF
25e30 59 0.5% 0.78 (0.51e1.19) 0.245 0.82 (0.55e1.23) 0.345
30e35 63 0.7% 1.09 (0.71e1.67) 0.683 1.11 (0.75e1.63) 0.606
35þ 33 0.6% 1.02 (0.63e1.65) 0.939 0.98 (0.58e1.64) 0.930
6 Months UTI
<18.5 5 3.6% 1.52 (0.61e3.78) 0.365 1.20 (0.48e2.95) 0.698
18.5e25 134 2.5% REF REF
25e30 268 2.2% 0.86 (0.70e1.07) 0.172 0.93 (0.74e1.17) 0.542
30e35 201 2.2% 0.87 (0.69e1.08) 0.206 0.93 (0.74e1.17) 0.542
35þ 112 2.1% 0.85 (0.66e1.10) 0.227 0.92 (0.68e1.25) 0.592
6 Months anaemia
<18.5 3 2.2% 0.85 (0.27e2.71) 0.789 0.75 (0.17e3.21) 0.693
18.5e25 142 2.6% REF REF
25e30 278 2.2% 0.85 (0.69e1.04) 0.116 0.92 (0.73e1.14) 0.436
30e35 163 1.8% 0.67 (0.53e0.84) 0.001 0.74 (0.58e0.94) 0.012
35þ 97 1.8% 0.69 (0.53e0.90) 0.006 0.76 (0.57e1.02) 0.065
6 Months MI n ¼ 32,169 n ¼ 31,226
<18.5 0 0.0% DROPPED DROPPED
18.5e25 31 0.6% REF REF
25e30 60 0.5% 0.89 (0.56e1.40) 0.604 0.89 (0.56e1.42) 0.628
30e35 30 0.3% 0.56 (0.33e0.96) 0.034 0.68 (0.38e1.23) 0.202
35þ 13 0.2% 0.45 (0.23e0.89) 0.022 0.77 (0.36e1.66) 0.508
6 Months stroke
<18.5 1 0.7% 1.38 (0.19e10.22) 0.751 3.79 (0.49e28.98) 0.200
18.5e25 29 0.5% REF REF
25e30 59 0.5% 0.84 (0.54e1.31) 0.444 0.87 (0.53e1.43) 0.593
30e35 36 0.4% 0.72 (0.44e1.18) 0.189 0.81 (0.47e1.39) 0.444
35þ 17 0.3% 0.60 (0.33e1.09) 0.091 0.83 (0.44e1.58) 0.577
6 Months death n ¼ 32,485 n ¼ 31,526
<18.5 4 2.9% 4.32 (1.52e12.30) 0.006 4.61 (1.64e13.01) 0.004
18.5e25 37 0.7% REF REF
25e30 77 0.6% 0.90 (0.61e1.34) 0.618 1.12 (0.74e1.70) 0.588
30e35 48 0.5% 0.75 (0.49e1.16) 0.198 1.21 (0.78e1.88) 0.397
35þ 16 0.3% 0.44 (0.24e0.79) 0.006 0.95 (0.50e1.78) 0.867
* Adjusted for age; gender; drinking; smoking; SES; year of surgery; previous occurrence of outcome; prior use of statins, antihypertensives, aspirin, antidepressants,
anticoagulants, antibiotics; previous diagnosis of diabetes, hypertension, chronic obstructive pulmonary disease, atrial ﬁbrillation, ischaemic heart disease.
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that, results would be biased towards the null, if at all. Nevertheless
residual confounding cannot be ruled out.
The consideration of 6-month outcomes may also have intro-
duced measurement error, with outcomes of interest increasingly
less likely to be related to surgery as time progresses. Consideration
of comparative incidence of complications at 6 weeks may there-
fore be of interest. However even in the large dataset considered
here, the low incidence of complications prohibited sufﬁcient po-
wer to investigate shorter-term outcomes and it is unlikely that 6-
month outcomes are sufﬁciently distal to surgery to warrant sub-
stantial misclassiﬁcation concerns.
The ascertainment of BMI through observational databases ne-
cessitates a compromise between minimising exclusions due tomissing data, and ensuring only relevant data is utilised. We used
the most recent BMI measure from the 5 years prior to surgery
based on the generally accepted stability of BMI and the desire to
include a reasonable sample of normal weight individuals who had
less frequent BMI measures. The average time between latest BMI
measure and surgery shortened with increasing obesity, however
with BMI remaining largely stable over time65, these differences (all
of less than a year) are unlikely to have signiﬁcantly affected our
results. Nevertheless use of historical BMI measures introduces
some measurement error, which may have moderately biased re-
sults towards the null.
Selection biases may also operate in regards to which patients
have an available BMI measure with patients with no BMI measure
generally having fewer co-morbidities and previous medications
G. Wallace et al. / Osteoarthritis and Cartilage 22 (2014) 918e927 925(Tables I and II). In the observational data utilised a patient must
ﬁrst present at the GP for a BMI measure to be possible. It is
therefore unsurprising that patients with less comorbidity are less
likely to have a recent BMI measure. This may have moderately
inﬂated estimates of the incidence of each complication although is
unlikely to impact on comparative estimates in this study. However,
anecdotal evidence from primary care physicians suggests that
whilst patients with apparent obesity would routinely have their
BMI measured regardless of visit reason, a normal or even moder-
ately underweight patient would not and would usually only be
measured in circumstances where there was greater health
concern. Accordingly the obese patients in our sample are more
likely to be otherwise healthy, whilst the normal weights and un-
derweights could be expected to be less healthy than the complete
cohort of patients considered for joint replacement. This potential
selection bias could bias ﬁndings towards suggesting that over-
weight and obese patients do relatively better than normal weight
patients. It is not possible to quantify this, however the use of BMI
measurements from a 5-year period helps to mitigate this concern.
A signiﬁcant limitation is the lack of adjustment for indication
for surgery. The CPRD is considered to be representative of the UK
population, and therefore the vast majority of joint replacement
operations will be due to osteoarthritis. The effect of residual
confounding is therefore expected to be minimal. Nevertheless the
impact of BMI on post-operative complications may differ accord-
ing to indication. Despite the large sample size, the low incidence of
complications and the expected low numbers of patients under-
going surgery for alternative indications such as fracture or rheu-
matoid arthritis prohibit investigation of such effect modiﬁcation in
this dataset. This remains an important question and warrants
future investigation.
In this context the results of this study should not be taken to
suggest that obesity is protective against mortality, although they
do reasonably suggest that surgeon selection of obese patients for
surgery is effective and that these obese patients are not at an
increased risk of mortality by 6 months. Underweight patients
however require closer attention and further research, since other
factors (such as a non-osteoarthritis indication for surgery which is
more common in thin people) might play a key role in explaining
our ﬁndings.
In accordance with the limited evidence base regarding the
outcomes of hip and knee replacement in obese patients, the 2008
NICE clinical guidelines on osteoarthritis have recommended that
“the restriction of referral for consideration of surgery based on
other health issues such as BMI, age or co-morbidities has no basis
in evidence. There are some groups of patients for whom the risks
of post-operative complication may be slightly higher or the long-
term outcomes of joint replacement worse but there is no evidence
supporting these as reasons to deny treatment”. Indeed decisions to
restrict access to surgery based on an increased risk of complica-
tions, requires consideration of the risks and beneﬁts in relation to
PROMS, cost-effectiveness and revision. Existing literature suggests
that obese patients achieve equivalent satisfaction following THR or
TKR22,23. Further research into the risks patients are prepared to
tolerate and the costs of obesity-related complications in the
context of the beneﬁts they can expect is required.
The current study supports the conclusion of NICE. Whilst an
increased risk of wound infection and DVT/PE was observed
amongst patients with increasing obesity, the absolute risks remain
low and effective prophylaxis is available and based on these ﬁnd-
ings, shouldbe considered for patientswho are overweight or obese.
Reassuringly the more serious side effects of MI and stroke are
rare, and 6-month mortality on the whole low. Given the inherent
selection biases in the surgeon-selected cohort, these results do not
advocate that surgery should be givenwithout consideration of BMI.However the results indicate that surgeons are effectively selecting
obese and overweight patients who are not at an increased risk of
such serious side effects for which prophylaxis is not available, and
therefore suggest that universal denial of surgery based on BMI
alone is unwarranted. That said, the ﬁndings suggest that more
attention should be directed towards the underweight patientswho
may be at an increased risk of death within 6 months of surgery.
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